Clinical trials in Heilbronn – page 39

987 clinical trials in Heilbronn, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Heilbronn at a glance

987

clinical trials

Research sites1

Quick filters

987 trials in Heilbronn

Open in trial search

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Carboplatin
Sponsor:GPOH gGmbH

Contact Research Centre

Malignant melanoma

Not yet recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with Metastatic Melanoma

Registered drug

Study of mRNA-4157 and Pembrolizumab for Patients with Metastatic Melanoma

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Enterobacter infection

Not yet recruiting

Study on the Effectiveness of Intestifix, Colistin Sulfate, and Vancomycin for Patients with Infections from Multidrug-Resistant Enterobacteriaceae

Registered drugNo placebo

Study on the Effectiveness of Intestifix, Colistin Sulfate, and Vancomycin for Patients with Infections from Multidrug-Resistant Enterobacteriaceae

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Colistin Sulfate
Sponsor:Goethe University Frankfurt

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Non-small cell lung cancer stage I

Not yet recruiting

Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

Registered drugNo placebo

Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Gastrooesophageal cancer+1

Not yet recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Cholangitis sclerosing

Not yet recruiting

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Norucholic Acid
Sponsor:Dr. Falk Pharma GmbH

Contact Research Centre

Skin cancer+1

Not yet recruiting

Study of DYP688 for Patients with Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

InvestigationalNo placebo

Study of DYP688 for Patients with Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:DYP688
Sponsor:Novartis Pharma AG

Contact Research Centre

Duchenne muscular dystrophy+1

Not yet recruiting

Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

Investigational

Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

Investigational

Germany

Participants:0–17 years · 18–64 years
Sponsor:Sarepta Therapeutics Inc.

Contact Research Centre

Pancreatic carcinoma metastatic

Not yet recruiting

Study on Chemotherapy with Liposomal Irinotecan, Oxaliplatin, and 5-Fluorouracil for Patients with Pancreatic Cancer Spread to the Liver

Registered drugNo placebo

Study on Chemotherapy with Liposomal Irinotecan, Oxaliplatin, and 5-Fluorouracil for Patients with Pancreatic Cancer Spread to the Liver

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:University Of Cologne

Contact Research Centre

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Azathioprine
Sponsor:Novartis Pharma AG

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Heilbronn

What the registry says about research in the country

01 Blood Cancers

Innovative trials focusing on Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia, testing novel drug combinations to improve patient outcomes. Research includes evaluating treatments for both adult and pediatric patients with various forms of leukemia.

Novel drug combinations for AML treatment
Targeted therapies for specific genetic mutations
Pediatric leukemia protocols

Studies aim to enhance survival rates and develop more effective treatment strategies for blood cancer patients.

02 Breast Cancer Research

Comprehensive studies addressing different types of breast cancer, particularly focusing on triple-negative breast cancer and HER2-positive disease. Research includes both early-stage and metastatic disease treatments.

Advanced therapeutic approaches for TNBC
Adjuvant therapy optimization
Personalized treatment strategies

Trials evaluate novel drug combinations and targeted therapies to improve patient outcomes.

03 Gastrointestinal Oncology

Research focusing on various digestive system cancers, including gastric cancer, colorectal cancer, and pancreatic cancer. Studies evaluate both early-stage and advanced disease treatments.

Advanced gastric cancer therapies
Preoperative treatment strategies
Novel combination approaches

Investigations aim to improve surgical outcomes and treatment effectiveness for GI cancers.

Back to Germany All countries